ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Adagene Logo

Adagene

Adagene has created a platform composed of unique, multi-purpose, antibody technologies and a growing pipeline of leading assets with novel MOAs. Empowered by precision engineering, Adagene identifies and selects antibody candidates that are most likely to achieve the desired biological effects. Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino acid sequence can adopt multiple structures and functions.

Quick overview

Suzhou City, China

Founded in 2011

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Public Company

Locations

1 Headquarter

Number of products

10 Products

Specialised areas

Therapeutics, Biotechnology, Medical

Products & services of Adagene

Adagene offers a wide range of products and services

Product: Dynamic Precision Library - Adagene

Product

Dynamic Precision Library - Adagene

Go to product >

Product: 新表位抗体(NEObody™) - Adagene

Product

新表位抗体(NEObody™) - Adagene

Go to product >

Product: 动态精准抗体平台 - Adagene

Product

动态精准抗体平台 - Adagene

Go to product >

Product: 强力抗体(POWERbody™) - Adagene

Product

强力抗体(POWERbody™) - Adagene

Go to product >

Product: 安全抗体(SAFEbody®) - Adagene

Product

安全抗体(SAFEbody®) - Adagene

Go to product >

Product: SAFEbody - Adagene

Product

SAFEbody - Adagene

Go to product >

Product: NEObody - Adagene

Product

NEObody - Adagene

Go to product >

Product: POWERbody - Adagene

Product

POWERbody - Adagene

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

China


Overall risk estimation:

High


ESG country scores

The ESG Data of countries are based on public sources

Environment

E

Grade (A-E)

View details

Social

C

Grade (A-E)

View details

Governance

E

Grade (A-E)

View details

Headquarter of Adagene

Adagene operates in 1 country around the world

City: Suzhou City

State: Jiangsu

Country: China

Locations of Adagene

Get an overview of the locations of Adagene

Location

Country

State

City

Headquarter

China

Jiangsu

Suzhou City

Frequently asked questions (FAQ) about Adagene

Some frequent questions that have been asked about Adagene

The company headquarter of Adagene is located in Suzhou City, Jiangsu, China. It's worth noting, that the company may have more locations

As of the latest available information Adagene has around 11-50 employees worldwide.

Adagene was founded in 2011

The company Adagene has it's main focus in the industries of Biotechnology

Competitors of Adagene

Check out some interesting alternative companies to Adagene

AvantGen's Logo

AvantGen

San Diego, United States

11-50 Employees

2006

We are laser-focused on getting what our partners need for the next stage. AvantGen provides a great platform and a dedicated, flexible, and communicative team that has resulted in success for multiple projects. Working with AvantGen on multiple antibody discovery projects was an outstanding experience. Interestingly, our popular AvantGeneer affinity maturation platform has been frequently used to optimize client antibodies that were originally discovered with hybridoma and human transgenic mouse platforms. Their innovative approach and collaborative mindset greatly contributed to the success of our program. Boosting the human innate immune system is a promising approach to cancer immunotherapy, and we have developed a Natural Killer (NK) cell engager platform. It’s important that both labeled and unlabeled antigens are QC’ed by provider, third party, and/or AvantGen.

Abtech Therapeutics's Logo

Abtech Therapeutics

Marseille, France

1-10 Employees

-

We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

Adivo's Logo

Adivo

Planegg, Germany

1-10 Employees

2012

The adivo technology platform allows de-novo identification of a panel of antibodies to select a drug candidate with optimal functionality, developability and low risk of immunogenicity. At adivo, Kathrin is driving the financing and business development strategy of the company and is managing adivo’s existing alliances. At adivo, Markus is leading the transition of antibody lead candidates from the company´s discovery platform into clinical development in close collaboration with a variety of internal and external parties. At adivo, Philipp drives the target identification process and technology development, as well as antibody discovery for both proprietary and partnered programs. We are excited to announce the expansion of an existing global research collaboration and introduce our latest technology platform FELIX. By developing adivo’s fully canine-based antibody library towards commercialization, we hope that we will be able to generate therapeutics for dogs that are both well tolerated and efficacious,” Dr. In 2018, adivo was founded focussing on therapeutic antibodies for dogs for unmet medical needs such as cancer and chronic inflammatory conditions. The adivo team aims to initially address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future.

Adimab's Logo

Adimab

Lebanon, United States

101-250 Employees

2007

We provide a full implementation of the Adimab Platform to enable your scientists to discover and optimize lead candidates within your existing workflow. We offer a suite of in vitro and in vivo discovery methods together with our engineered yeast to deliver therapeutic leads to our partners. We offer a variety of bispecific formats that cover a wide range of biological functionality.

Ab Studio's Logo

Ab Studio

Hayward, United States

11-50 Employees

2017

We are a biotech startup in the San Francisco Bay Area founded in February 2017. Our goal is to close the gap between antibody discovery and therapeutic antibody development by developing the next generation of therapeutic antibodies. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, infectious diseases, and CNS diseases, by combining conventional approaches with computer-aided antibody design (CAAD). Our founder and lead scientists have extensive expertise in the fields of therapeutic antibody discovery, lead selection, engineering, humanization, and optimization. We believe in quality-by-design and have established several CAAD-based unique technology platforms for antibody development and are in the process of developing more platforms and therapeutics. Founder, Yue Liu, is a leading scientist with extensive expertise in therapeutic antibody discovery and computer-aided design. Joining Yue, the team is composed of experts in antibody engineering, B-cell cloning, cancer biology, immunology and virology.

GigaGen's Logo

GigaGen

South San Francisco, United States

11-50 Employees

2010

GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases. GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies. GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development. GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates. Biocentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute. GigaGen’s platform technologies significantly increase the productivity and speed of target and drug discovery, quickly filling a growing pipeline of transformative antibody drugs.